OBJECTIVES: Even after curative resection, a significant fraction of patients with stage I non-small-cell lung cancer (NSCLC) die primarily because of systemic relapse. The purpose of the present study was to investigate the risk factors for both recurrence and poor survival in patients with pathological ( p-) stage I NSCLC.
INTRODUCTION
Lung cancer is a common malignancy and a major cause of cancer-related deaths in most industrialized countries. Approximately 85% of lung cancer cases are non-small-cell lung cancer (NSCLC) cases, and these comprise a heterogeneous group of histology types [1] . Because a large percentage of the cases are diagnosed at an advanced stage, the prognosis for patients with NSCLC has not been satisfactory.
In recent years, with the development of high-resolution computed tomography (CT) scanners proficient in detecting small tumours [2] , we have an increased opportunity of encountering early-stage NSCLC. Therefore, excellent 5-year survival rates for completely resected stage IA (83.7%) and stage IB (76.0%) NSCLC has been reported in Japan [3] .
Even after curative resection, a significant fraction of patients with stage I NSCLC die, primarily because of systemic relapse [4] . This implies that other factors in addition to pathological ( p-) stage affect the surgical outcomes of NSCLC patients.
We conducted a retrospective study based on a single institution to investigate the risk factors for both recurrence and survival in patients with p-stage I NSCLC.
MATERIALS AND METHODS
Between September 2002 and December 2009, 962 patients underwent complete surgical resection for NSCLC at the Shizuoka Cancer Center Hospital, Shizuoka, Japan. Of these, we retrospectively reviewed 467 consecutive patients with p-stage I disease. Patients with multiple lung tumours or malignancies from other organs and those who had undergone preoperative therapies were excluded. Approval from the institutional review board was obtained. The medical records of each patient were examined to determine age, gender, smoking history, serum carcinoembryonic antigen (CEA) levels, serum cytokeratin 19 fragment (CYFRA21-1) levels, surgical procedure, tumour histology, p-stage, angiolymphatic invasion, differentiation grade, adjuvant chemotherapy, recurrence and survival. If necessary, the follow-up information was obtained via a posted questionnaire completed by the local chest physician or general practitioner. Histology was evaluated according to the latest World Health Organization classification of lung tumours [5] . Staging was determined according to the seventh edition of the International Union against Cancer (UICC) tumour-node-metastasis (TNM) staging system [6] .
We performed lobectomy or pneumonectomy with systemic mediastinal lymph node dissection as the standard surgical treatment. Segmentectomy or wedge resection was performed only on patients with tumours showing a greater proportion of ground-glass opacity on CT or on those with major comorbidities. Adjuvant chemotherapy with oral tegafur/uracil (UFT) at 400 mg/day was considered for stage IB or IA T1b patients who had undergone standard surgical treatment. Elderly patients (75 years or older), those with a performance status of ≥2, and those who refused further treatment were excluded as candidates for adjuvant chemotherapy.
Both serum CEA and CYFRA21-1 concentrations were measured within the 1-month period before surgery. The CEA concentration was measured using an ARCHITECT(r) kit (Abbott Japan, Tokyo, Japan), while the CYFRA21-1 concentration was measured using an Lumipulse Presto(r) kit (FUJIREBIO, Inc., Tokyo, Japan). According to the manufacturer of these kits, the upper limits of the percentiles of healthy individuals for CEA and CYFRA21-1 levels were 5.0 and 3.5 ng/ml, respectively. Therefore, the cut-off point for these tumour markers was set to the same level as the upper limits in the present study.
Angiolymphatic invasion was defined as the presence of neoplastic cells within an arterial, venous or lymphatic lumen during routine histological evaluation with haematoxylin and eosin, elastic van Gieson (EVG) and D2-40 stains. Because of the retrospective nature of this study, the distinction between arterial, venous and lymphatic invasion was not available in some cases. Therefore, these categories were merged into a single variable (angiolymphatic invasion). The presence or absence of angiolymphatic invasion was assessed in the largest cross-sections of the tumour in every specimen. The grade of differentiation was classified as well-differentiated, moderately differentiated and poorly differentiated carcinomas according to the degree of structural and cytological atypia. Differentiation in squamous cell carcinoma was determined on the basis of the degree of keratinization and the presence of intercellular bridges. Poorly differentiated squamous cell carcinoma was defined as a tumour in which these features were faint and that had a solid pattern. Adenocarcinoma, which is largely composed of malignant glandular epithelium, was evaluated according to lepidic, tubular and papillary structure. Poorly differentiated adenocarcinoma was defined as a tumour with a solid pattern, without any clear gland formation. The grade of differentiation was not determined for the other histology types. Pathological evaluation was performed prospectively by ≥2 experienced pathologists.
In the present study, patients were subdivided into three groups based on their serum CEA levels and p-stage: patients with both high serum CEA levels and p-stage IB (high-risk group), those with high serum CEA levels alone and p-stage IB alone (moderate-risk group), and those with neither high serum CEA levels nor p-stage IB (low-risk group).
Statistical analysis
Disease-free survival (DFS) was calculated as the period from surgical resection until the initial detection of recurrences, and overall survival (OS) was calculated as the period from surgical resection until death or the date of the last follow-up evaluation. The KaplanMeier method was used to generate survival curves, and survival differences were analysed using the log-rank test. Variables with a P-value of <0.2 after univariate analysis were entered into multivariate analysis using the Cox proportional hazards model to evaluate their independent prognostic roles for DFS and OS. A P-value of <0.05 was considered significant. All statistical analyses were performed using the JMP 9 software (SAS Institute, Cary, NC, USA).
RESULTS
The clinicopathological factors of the patients (n = 467) are listed in Table 1 . The study population comprised 234 men and 233 women, with a median age at surgery of 67 years (range, 20-90 years). Eighty-nine patients had a high serum CEA level and 378 (Fig. 1) .
Predictors of disease-free survival according to univariate analysis
The results of univariate analysis for recurrence are summarized in Table 2 . The clinicopathological factors of serum CEA levels (P < 0.001) and p-stage (P < 0.001) were significant factors for recurrence.
Predictors of disease-free survival according to multivariate analysis
Multivariate analysis for recurrence was performed using three factors, and the results are summarized in Table 3 . High serum CEA levels [hazard ratio (HR) = 2.53, 95% CI: 1.26-5.03, P = 0.010] and p-stage IB (HR = 4.08, 95% CI: 1.99-8.70, P < 0.001) were found to be independent factors for recurrence.
Predictors of overall survival according to univariate analysis
The results of univariate analysis for survival are summarized in Table 2 . The clinicopathological factors of age, gender, smoking history, serum CEA levels, tumour histology, p-stage, angiolymphatic invasion and differentiation grade were significant prognostic factors for survival. 
Predictors of overall survival according to multivariate analysis
Multivariate analysis for survival was performed using eight factors, and the results are summarized in Table 4 . Older age (HR = 3.02, 95% CI: 1.43-6.93, P = 0.003), high serum CEA levels (HR = 2.22, CI: 1.01-4.81, P = 0.048) and p-stage IB (HR = 2.34, 95% CI: 1.06-5.24, P = 0.035) were found to be independent prognostic factors for poor survival. Angiolymphatic invasion was associated with an increased HR; however, this result did not reach statistical significance (HR = 2.00, 95% CI: 0.96-4.09, P = 0.062).
Disease-free survival and overall survival curves based on serum CEA levels and p-stage
The high-, moderate-and low-risk groups included 57, 124 and 286 patients, respectively. Five-year DFS rates in these subgroups were 69, 88 and 97%, respectively (P < 0.001). Five-year OS rates in these subgroups were 70, 93 and 97%, respectively (P < 0.001). These survival curves are shown in Fig. 2 .
Risk of recurrence and death in the high-risk group
By multiplying the HRs for high serum CEA levels and p-stage IB, the risks of recurrence and death in the high-risk group were estimated to be 10.3 (2.53 × 4.08) and 5.2 (2.22 × 2.34) times higher than those observed in the low-risk group, respectively.
DISCUSSION
Several putative prognostic factors for NSCLC patients such as angiolymphatic invasion, differentiation grade, serum CEA levels and serum CYFRA21-1 levels are not taken into account in the current TNM staging system. We performed a comprehensive examination to elucidate the correlation between various clinicopathological factors and surgical outcomes with a relatively large sample size of 467 p-stage I NSCLC patients. In the present study, angiolymphatic invasion was found to be a marginally independent prognostic factor, but this result did not reach statistical significance. Schuchert et al. [7] reported that angiolymphatic invasion was an independent predictor of recurrence and poor survival in p-stage I NSCLC patients, indicating the need for adjuvant systemic therapy after curative resection for those harbouring this factor. This discrepancy might be explained by interobserver bias and methodological differences in evaluating angiolymphatic invasion [8] . We routinely performed EVG and D2-40 staining in each case, and we believe that this procedure enabled the precise evaluation of angiolymphatic invasion.
We showed that moderately to poorly differentiated carcinoma was significantly correlated with poor survival when compared with well-differentiated carcinoma in univariate analysis. However, the prognostic significance of the extent of differentiation was not retained following multivariate analysis. Sun et al. [9] reported that those with a less-differentiated carcinoma had an increased risk of recurrence (HR, 2.1 and 1.4, for poorly/undifferentiated and moderately differentiated carcinoma, respectively, compared with well-differentiated carcinoma) among 1302 patients with completely resected NSCLC, offering a possible explanation for a shortened survival. Similarly, some reports have demonstrated that the grade of differentiation was an independent factor for recurrence and survival in p-stage I NSCLC patients [10, 11] . These diverse prognostic outcomes were possibly because of factors such as sample size, histological diversity in NSCLC and inconsistent grading criteria among pathologists [9] . These histological prognostic factors are clearly subject to intrinsic interobserver bias. Therefore, quantitative information from evaluation using tumour markers offers advantages over histological assessment.
Pujol et al. [12] reported the prognostic value of serum CYFRA21-1 levels (HR = 1.88, P < 0.001) in a meta-analysis of 2063 NSCLC patients with any stage of disease. However, there was no statistical significance when the results were restricted to the surgically treated population (HR = 1.41, P = 0.055). Blankenburg et al. [13] and Matsuoka et al. [14] have reported that serum CYFRA21-1 levels have no prognostic value in p-stage I NSCLC patients, consistent with our results. In the meta-analysis mentioned above, the predominant tumour histology was squamous cell carcinoma (accounting for approximately half of all cases) and this predominance may account for the discrepancy between these studies. However, even after restricting our analysis to patients with squamous cell carcinoma, we failed to show any statistical significance for serum CYFRA21-1 levels in relation to DFS and OS (P = 0.27, P = 0.16, respectively). The prognostic significance of serum CYFRA21-1 levels for patients with resected NSCLC needs to be validated in additional studies.
Many reports have referred to the prognostic significance of high serum CEA levels both in clinical (c-) and p-stage I NSCLC patients [14] [15] [16] [17] [18] [19] [20] . Moreover, the combined evaluation of serum CEA levels with vascular invasion or CT findings has been advocated to predict poor outcomes for small-sized lung adenocarcinoma cases [21, 22] . In the present study, we found that high serum CEA levels were independently associated with recurrence and poor survival, and combined evaluation of serum CEA levels with p-stage enabled us to identify a subgroup of patients with poor outcome among the p-stage I NSCLC patients. The 5-year DFS and OS rates of the high-risk group were 69 and 70%, respectively, whereas those of the low-risk group were 97 and 97%, respectively. We estimated a considerably increased risk of recurrence and death in the high-risk group compared with that in the low-risk group. In 1999, Suzuki et al. [20] reported a similar outcome for c-stage I NSCLC patients. The risk of death in patients with c-T2 disease (according to the fourth international TNM staging system) and high serum CEA levels (the same cut-off value as that of our study) was 4.14 times higher than that of the overall c-stage I NSCLC population. They indicated the need for induction chemotherapy for this subgroup [20] . In this context, the high-risk group in the present study might have benefited from adjuvant chemotherapy. However, because our study included 39 patients who had undergone adjuvant chemotherapy with UFT, it was difficult to evaluate the subsets of p-stage I NSCLC patients who would have required adjuvant chemotherapy.
Our results highlight the prognostic value of serum CEA levels in addition to p-stage, the well-established prognosticator. If our findings can be generalized to patients with other p-stages, this parameter might be considered as an independent factor affecting survival beyond the current TNM staging system.
In conclusion, high serum CEA levels together with p-stage IB were risk factors for both recurrence and poor survival in p-stage I NSCLC patients.
